Drugs by active ingredient

Monthly reports by species, five years

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

2016 covers reports received through March 2026 only.

Signs listed in reports

share of diethylcarbamazine citrate reports listing the termall dog reports

1. No sign[no clinical sign was reported]20.7%91
2. Accidental exposure[exposure that was not intended]18.4%81
3. Vomiting18.2%80
4. Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]9.1%40
5. Depression[dull, quiet or withdrawn]8.9%39
6. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]6.4%28
7. Diarrhoea[diarrhea]5.9%26
8. Anorexia[not eating]5.7%25
9. Unpalatable[legacy FDA term: the animal would not take it]5.2%23
10. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]4.5%20
11. Ineffective, heartworm adults[legacy FDA term: the product did not have the expected effect (heartworm adults)]3.9%17
12. Product Defect, General[a product quality report, not a sign in an animal]3.2%14
13. Convulsion[seizure]2.7%12
14. Seal, Abnormal[a product quality report, not a sign in an animal]2.7%12
15. Unclassifiable adverse event[event that fits no dictionary term]2.5%11
16. Death2%9
17. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]2%9
18. Elevated total bilirubin[bilirubin above the normal range]2%9
19. Icterus[jaundice (yellowing)]2%9
20. Tablets, Abnormal[a product quality report, not a sign in an animal]2%9
21. Anaemia NOS[low red blood cell count]1.8%8
22. Collapse1.8%8
23. Elevated creatinine[a kidney value above the normal range]1.6%7
24. Pruritus[itching]1.6%7
25. Weakness1.6%7
26. Elevated liver enzymes[liver enzymes above the normal range]1.4%6
27. Restlessness1.1%5
28. Thrombocytopenia[low platelet count]1.1%5
29. Underfilling, Package[a product quality report, not a sign in an animal]1.1%5
30. Ataxia[unsteady, uncoordinated movement]0.9%4

Top 30 of 152 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Coloured bar: reports naming diethylcarbamazine citrate. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Route of administration stated in reports: oral (373), topical (1).

In context

This set accounts for 100% of all reports naming diethylcarbamazine citrate, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.